Division of Vascular Surgery, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif.
Division of Vascular Surgery, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif.
J Vasc Surg Venous Lymphat Disord. 2017 Sep;5(5):667-676.e1. doi: 10.1016/j.jvsv.2017.02.009. Epub 2017 May 12.
Patients with May-Thurner syndrome (MTS) present with a spectrum of findings ranging from mild left leg edema to extensive iliofemoral deep venous thrombosis (DVT). Whereas asymptomatic left common iliac vein (LCIV) compression can be seen in a high proportion of normal individuals on axial imaging, the percentage of these persons with symptomatic compression is small, and debate exists about the optimal clinical and diagnostic criteria to treat these lesions in patients with symptomatic venous disease. We evaluated our approach to venography-guided therapy for individuals with symptomatic LCIV compression and report the outcomes.
All patients with suspected May-Thurner compression of the LCIV between 2008 and 2015 were analyzed retrospectively. Patients with chronic iliocaval lesions not associated with compression of the LCIV were excluded from analysis. Criteria for intervention included LCIV compression in the setting of (1) leg edema/venous claudication with associated venographic findings (collateralization, iliac contrast stagnation, and contralateral cross cross-filling), or (2) left leg deep venous thrombosis. Outcome measures included presenting Clinical, Etiology, Anatomy, Pathophysiology (CEAP) score, postintervention CEAP score, primary patency, and secondary patency. Technical success was defined as successful stent implantation without intraoperative device complications, establishment of in-line central venous flow, and less than 30% residual LCIV stenosis.
Of the 63 patients evaluated, 32 (51%) had nonthrombotic MTS and presented with leg edema (100%) or venous claudication (47%). Thirty-one patients (49%) had thrombotic MTS and presented with acute (26%) or chronic (71%) DVT, leg edema (100%), or venous claudication (74%). The mean presenting CEAP score was 3.06 and 3.23 for nonthrombotic and thrombotic MTS, respectively. Forty-four patients (70%) underwent successful intervention with primary stenting (70%) or thrombolysis and stenting (30%); 14 nonthrombotic MTS patients were treated conservatively with compression therapy alone, and 5 thrombotic MTS patients were treated with lysis or angioplasty alone. Clinical improvement and decrease in CEAP score occurred in 95% and 77% of stented patients compared with 58% and 32% of nonstented patients. Complete symptom resolution was achieved in 48% of patients overall, or 64% of stented patients and only 21% of nonstented patients. Complications included two early reocclusions. Primary and secondary 2-year patency rates were 93% and 97% (mean follow-up, 20.3 months) for stented patients.
Venography-guided treatment of MTS is associated with excellent 1-year patency rates and a significant reduction in symptoms and CEAP score. Treating symptomatic MTS patients on the basis of physiologically relevant venographic findings rather than by intravascular ultrasound imaging alone results in excellent long-term patency and clinical outcomes but may result in undertreatment of some patients who could benefit from stent implantation.
梅-特纳综合征(May-Thurner syndrome,MTS)患者的表现从轻度左下肢水肿到广泛的髂股深静脉血栓形成(DVT)不等。虽然在轴向成像中可以看到相当比例的无症状左髂总静脉(LCIV)受压,但这些存在症状性压迫的患者比例很小,而且对于有症状静脉疾病患者治疗这些病变的最佳临床和诊断标准存在争议。我们评估了我们对有症状 LCIV 受压患者行静脉造影引导治疗的方法,并报告了结果。
回顾性分析了 2008 年至 2015 年间所有疑似 MTS 压迫 LCIV 的患者。排除了与 LCIV 压迫无关的慢性髂股静脉病变的患者。干预的标准包括(1)腿部水肿/静脉跛行伴相关静脉造影发现(侧支循环、髂静脉造影剂停滞和对侧交叉充盈),或(2)左下肢深静脉血栓形成。观察指标包括就诊时临床、病因、解剖、病理生理(CEAP)评分、干预后 CEAP 评分、一期通畅率和二期通畅率。技术成功定义为术中无器械并发症成功植入支架、建立中央静脉直线血流以及 LCIV 残余狭窄小于 30%。
在评估的 63 例患者中,32 例(51%)为非血栓性 MTS,表现为腿部水肿(100%)或静脉跛行(47%)。31 例(49%)为血栓性 MTS,表现为急性(26%)或慢性(71%)DVT、腿部水肿(100%)或静脉跛行(74%)。非血栓性 MTS 和血栓性 MTS 的平均就诊时 CEAP 评分为 3.06 和 3.23。44 例(70%)患者成功接受了介入治疗,包括单纯支架置入术(70%)或溶栓联合支架置入术(30%);14 例非血栓性 MTS 患者单纯接受保守治疗,即压迫治疗,5 例血栓性 MTS 患者单纯接受溶栓或血管成形术治疗。与未支架置入的患者相比,支架置入的患者临床改善和 CEAP 评分降低分别为 95%和 77%,而非支架置入的患者分别为 58%和 32%。总的完全症状缓解率为 48%,支架置入的患者为 64%,而非支架置入的患者为 21%。并发症包括 2 例早期再闭塞。支架置入患者的 1 年和 2 年一期通畅率分别为 93%和 97%(平均随访 20.3 个月)。
静脉造影引导治疗 MTS 具有良好的 1 年通畅率,并显著改善症状和 CEAP 评分。根据有生理意义的静脉造影发现而非单纯血管内超声成像来治疗有症状的 MTS 患者,可获得良好的长期通畅率和临床效果,但可能导致一些可能受益于支架置入的患者治疗不足。